L

La Jolla Pharmaceutical Co
F:LJPP

Watchlist Manager
La Jolla Pharmaceutical Co
F:LJPP
Watchlist
Price: 6.072 EUR Market Closed
Market Cap: 151.2m EUR

Operating Margin
La Jolla Pharmaceutical Co

-5.5%
Current
-218%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5.5%
=
Operating Profit
-2.6m
/
Revenue
46.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
La Jolla Pharmaceutical Co
F:LJPP
151.5m EUR
-6%
IL
Can Fite Biopharma Ltd
TASE:CANF
168.5T ILS
-1 487%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
382.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
175.6B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
153.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.7B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD
28%
AU
CSL Ltd
ASX:CSL
84.9B AUD
26%
NL
argenx SE
XBRU:ARGX
42.8B EUR
22%
No Stocks Found

La Jolla Pharmaceutical Co
Glance View

Market Cap
151.5m EUR
Industry
Biotechnology

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.

LJPP Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-5.5%
=
Operating Profit
-2.6m
/
Revenue
46.5m
What is the Operating Margin of La Jolla Pharmaceutical Co?

Based on La Jolla Pharmaceutical Co's most recent financial statements, the company has Operating Margin of -5.5%.

Back to Top